Kornimate/medical-research-clean huggingface dataset:
apples in night shift

Conditions: Night Work

Summary: background: emergency doctors face a highly stressful work environment during night shifts. long-term night shift work can lead to sleep deprivation, fatigue accumulation, and disruption of the biological clock, which may affect doctors' work efficiency and physical and mental health. there are various health interventions for night shift doctors, one of which is an interesting practice of carrying an apple as a symbol of the "night shift deity" to relieve anxiety and improve work efficiency. although this behavior is not supported by sufficient scientific evidence, it has become a common habit among some doctors during night shifts due to its simplicity, low risk, and ritualistic nature. objective: to assess whether carrying an apple during night shifts can significantly reduce fatigue, decrease work intensity, and enhance work experience for emergency doctors. design: single-center, open-label, randomized controlled trial. participants: several doctors with a total of 60 emergency working night shifts. primary outcome: average number of patients per night shift. sample size: the study plans to recruit several doctors with a total of 60 emergency night shifts and randomly assign them to the experimental group and the control group. one doctor can be randomized for many times.

background: emergency doctors face a highly stressful work environment during night shifts. long-term night shift work can lead to sleep deprivation, fatigue accumulation, and disruption of the biological clock, which may affect doctors' work efficiency and physical and mental health. there are various health interventions for night shift doctors, one of which is an interesting practice of carrying an apple as a symbol of the "night shift deity" to relieve anxiety and improve work efficiency. although this behavior is not supported by sufficient scientific evidence, it has become a common habit among some doctors during night shifts due to its simplicity, low risk, and ritualistic nature. objective: to assess whether carrying an apple during night shifts can significantly reduce fatigue, decrease work intensity, and enhance work experience for emergency doctors. design: single-center, open-label, randomized controlled trial. participants: several doctors with a total of 60 emergency working night shifts. primary outcome: average number of patients per night shift. sample size: the study plans to recruit several doctors with a total of 60 emergency night shifts and randomly assign them to the experimental group and the control group. one doctor can be randomized for many times.

Eligibility criteria:
inclusion criteria: doctors who have a night shift in the emergency department of gynaecology with at least two weeks experience. exclusion criteria: doctors who refuse to join the study

Keywords: night shift apple doctor emergency department
a study of vedolizumab and biologic agents in participants with inflammatory bowel disease (ibd)

Conditions: Inflammatory Bowel Disease (IBD); Ulcerative Colitis; Crohn's Disease

Summary: this is a non-interventional, retrospective study of adult participants with ibd. ibd consists of either ulcerative colitis (uc) or crohn's disease (cd). the study will review the clinical data previously collected during february 2007 to march 2020 of approximately 724 participants who have had treatment with adalimumab, infliximab, golimumab, or vedolizumab in taiwan.

this is a non-interventional, retrospective study in newly diagnosed ibd participants (uc or cd) treated with biologics. the study will assess ibd relapse, effectiveness, and safety of biologic treatments in ibd participants. the study will enroll approximately 724 participants. the data will be collected from the electronic medical record (emr) database of selected medical centers in taiwan. ibd participants who were evaluated and treated at the participating sites between 01 february 2007 to 31 march 2020 will be included. participants will be assigned to the following two observational cohorts based on pathological diagnosis: * cohort 1: participants with biologics discontinuation * cohort 2: participants treated with biologics this multi-center trial will be conducted in taiwan. the overall duration of the study will be approximately 15 months.

Eligibility criteria:
inclusion criteria: 1. diagnosed during february 2008 to march 2020 (or per local institutional review board \[irb\] permitted date). * cd (international classification of diseases, ninth revision, clinical modification \[icd-9-cm\]: 555.x or international classification of diseases, tenth revision, clinical modification \[icd-10-cm\]: k50.xx, k50.xxx) * uc (icd-9-cm: 556.x or icd-10-cm: k51.xx, k51.xxx). 2. had received any dose of biologics for ibd treatment, including vedolizumab adalimumab, infliximab or golimumab, from february 2008 to march 2020 (or per local irb permitted date). exclusion criteria: 1. participants with any suspected diagnosis of cd or uc within one year before the initial date of confirmed ibd diagnosis will be excluded.

Keywords: drug therapy
4k versus 3d laparoscopic colporraphy by surgeons in training: a prospective randomized trial

Conditions: Uterine Fibroid; Uterine Bleeding; Uterine Prolapse

Summary: this prospective randomized trial aims to assess if the operative time of vaginal cuff suture performed by trainees could be reduced using 3d laparoscopy instead of 4k laparoscopy.

all patients with benign uterine pathology at preoperative examinations (pelvic ultrasound and / or magnetic resonance and / or ct) and with indication for total laparoscopic hysterectomy with consequently need for laparoscopic suture of the vaginal cuff, will be enrolled in the study. - i time/out of protocol time (performed by expert surgeons) while under general anesthesia, the patient is positioned in the dorsal lithotomic position with both legs supported in stirrups with a trendelenburg tilt and arms along the body. a four disposable or reusable, sterile trocar transperitoneal approach is used. a 10 mm port is inserted at the umbilicus for the telescope. once pneumoperitoneum (12 mmhg) is achieved, intra-abdominal visualization will be obtained with a 0° 4k high-definition telescope (visera uhd 4k 10 mm, olympus winter \& ibe gmbh, hamburg - germany) or with 0° 3d laparoscopy high-definition (olympus winter \& ibe gmbh, hamburg - germany). two additional 5 mm ports are placed under direct visualization, in the right lower abdomen medial to the right obliterated umbilical artery and in the left lower abdomen lateral to the inferior epigastric vessels. one more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. the instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system. clermont ferrand uterine manipulator (model k.storz endoskope,tuttlingen, germany) is optionally used to move the uterus. total hysterectomy is then performed according to standard technique. - ii time/protocol time (performed by surgeon in training) the vaginal vault is closed with a 0 vycril suture laparoscopically (continuous suture). in order to avoid excess operating time, 15 min was allocated for completion of cuff closure by surgeons-in-training, after which time the attending surgeon took over this task. operative time, estimated blood loss, incidence of intra or post-operative complications, postoperative pain, days of hospitalization and costs will be recordered

Eligibility criteria:
inclusion criteria: * patients suffering from benign gynecological pathology (uterine fibromatosis, abnormal blood loss, complex hyperplasia with atypia, uterine prolapse) with indication for total uterine hysterectomy and consequently need for laparoscopic suture of the vaginal cuff * american society of anesthesiologists (asa) class \< 3 * patient's informed consent exclusion criteria: * suspected neoplastic pathology * patients not eligible for surgery * actual pregnancies or pelvic inflammatory disease

Keywords: 4k laparoscopy 3d laparoscopy surgeons in training
comparative study of hexvix blue light cystoscopy and white light cystoscopy in the detection of bladder cancer

Conditions: Bladder Cancer

Summary: a study to compare hexvix blue light cstoscopy with standard white light cystoscopy in the detection of bladder cancer.

a phase iii, prospective, within patient controlled, multi-center study to compare blue light cystoscopy with hexvix and standard white light cystoscopy in the detection of bladder cancer, to evaluate the efficacy and safety of hexvix blue light cystoscopy in chinese population. patients with suspicious or confirmed bladder cancer will participate in the trial and undergo blue light cystoscopy with hexvix in addition to the standard white light cystoscopy. specific clinical questions will be asked: * what is the proportion of patients who have at least one specific kind of tumor found by blue light cystoscopy with hexvix but not by white light cystoscopy? * what is the proportion of patients who have at least one specific kind of lesion found by blue light cystoscopy with hexvix but not by white light cystoscopy? * what is the proportion of false positive lesions detected with hexvix blue light cystoscopy and white light cystoscopy? * what is the proportion of patients with adverse events (ae) during the study?

Eligibility criteria:
inclusion criteria: 1. volunteer to participate in clinical study; thoroughly informed, signed and dated the informed consent form; willing to follow and have the ability to complete all trial procedures. 2. suspicious or confirmed patients with bladder cancer. 3. age 18 or older. exclusion criteria: 1. gross haematuria. (note: gross haematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may visually limit cystoscopy. where the haematuria is light, the patient should not be excluded, if in the investigator's opinion, rinsing and/or electro-cautery during cystoscopy will alleviate the possible interference with cystoscopy). 2. patients who have received bcg immunotherapy or intravesical chemotherapy within the past 6 weeks prior to the procedure. 3. porphyria. 4. known allergy to hexaminolevulinate hydrochloride or a similar compound. 5. pregnancy or breast-feeding or women who plan to become pregnant during the trial, and men or women who are unwilling to take barrier contraceptives from 2 weeks before application of investigational medication to 28 days after application of investigational medication (note: all women of child-bearing potential must document a negative urine pregnancy test before study inclusion and use adequate contraception during the study. 6. participation in other clinical studies with investigational drugs either concurrently or within the last 30 days. 7. patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. 8. patients that the investigator assessed unsuitable to the study. 9. subjects with contraindications to white light cystoscopy.
estimation method of 24-hour urinary sodium excretion by using spot urine for chinese population

Conditions: Urinary Sodium Excretion; Salt Intakes

Summary: the accurate evaluation of daily salt or sodium intake is difficult to implement in clinical practice and large epidemiological studies. 24-h urinary sodium excretion (use) is considered the gold standard, but is expensive and has a high participant burden. to further explore the association between 24-h use and spot urines in chinese population, it was proposed that using collected multiple spot urine samples could be estimated for 24-h use in chinese children and adults.

specific aims 1. to collect multiple spot urine samples and a 24-h urine sample in a population of chinese children and adults. all participants will collect a spot urine in separate jugs during the 24-h period, recording every urination time. 2. validate previous finding that 24-h use is estimated inaccurately by using only the second morning void. 3. explore a statistical formula to estimate 24-h use by multi-time spot urine. the study plan to enroll 200 children and 100 adults to collect a whole 24-h urine spot by spot continuously. after a laboratory examination of sodium concentration from both spot urine samples and 24-h urine sample, the exploratory estimation using multi-spot urine to assess 24-h urinary sodium excretion will analyzed statistically. the validation for the estimation method will be conducted in chinese population as well. urine sodium and potassium concentration in each urine specimen will be determined by ion selective electrode methods and creatinine using enzymatic methods.the model established by using linear model step by step. and the validation analysis conducted through correlation analysis, bias distribution, residual analysis and bland-altman plot to assess accuracy. all statistics analysis will be conducted using statistical analysis system software version 9.4.

Eligibility criteria:
inclusion criteria: * aged 5-60 years * provide written informed consent * without any renal diseases or conditions which could affect renal function exclusion criteria: * pregnant * taking diuretic medicine or pharmaceutical using patients, e.g. some hypertension or heart diseases patients * cancer patients or some other severe patient

Keywords: urinary sodium excretion 24-hout urine salt intakes hypertension
postoperative analgesia with erector spinae plane block after pectus excavatum repair in children

Conditions: Pectus Excavatum

Summary: the purpose of this study is to evaluate the efficacy of erector spinae plane (esp) block in children after pectus excavatum repair (nuss procedure).


Eligibility criteria:
inclusion criteria: * 30 children aged between 3 and 7 years who undergo nuss bar insertion due to pectus excavatum exclusion criteria: * allergy to opioid * allergy to local anesthetics * disease in heart, lung, kidney, and liver * coagulation disorder * disease in central and peripheral nervous system
educating smokers about lung cancer screening using tobacco quitlines

Conditions: Lung Carcinoma

Summary: this implementation study will examine the best ways to refer heavy smokers to information about lung cancer screening.

primary objective: i. to increase the number of smokers eligible for lung cancer screening (lcs) who receive high-quality educational materials about lcs through tobacco quitlines. outline: call center staff: participants undergo training consisting of a 60-minute educational session. callers substudy: participants are referred to lung cancer screening educational materials. participants also complete questionnaires at 1 week and 6 months after referral to educational materials.

Eligibility criteria:
inclusion criteria: * quitline call center staff * staff member of a quitline * aged 18 years and above * callers (smokers who contact the quitline about smoking cessation services) inclusion criteria * callers 55-80 years of age * current smoker, or former smoker with a cessation history of \< 15 years * \>= 30 pack-year smoking history * english-speaking exclusion criteria: * callers (smokers who contact the quitline about smoking cessation services) exclusion criteria * history of lung cancer by self-report
comparison study of operation and peit for small, solitary hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to choose the preferred treatment modality for solitary, small hepatocellular carcinoma.

to compare the below things between operation group and percutaneous ethanol injection therapy (peit) group: 1. survival * 5 year overall survival rate * disease free survival rate 2. recurrence * cumulative recurrence rate

Eligibility criteria:
inclusion criteria: * the evidences of hepatitis b virus (hbv)\&/or hepatitis c virus (hcv) infection or liver cirrhosis * single tumor nodule with child-pugh classification a (serum albumin ≥ 3.2 g/dl) * the maximal, longest diameter of tumor mass measured by ct finding should be less than 2 cm * only for the newly detected hccs which were not treated before * it should be compatible with the typical finding of hepatocellular carcinomas (hccs) radiologically (md ct or dynamic mri) * without portal hypertension exclusion criteria: * in case of hepatic vein or portal vein invasion radiologically (ct or mri)

Keywords: hcc, operation, percutaneous ethanol injection
pharmacokinetic analysis of high dose methotrexate in pediatric lymphoblastic malignancies

Conditions: Methotrexate Adverse Reaction

Summary: \* the pharmacokinetics of mtx were assessed with regards to the relevance of several different patient specific factors in 291 pediatric patients, who were administered with high dose of mtx. population pharmacokinetics of mtx analysis was performed by using nonlinear mixed effects modeling.

* methotrexate (mtx) is one of the critical components for treating all forms of acute lymphoblastic leukemia (all), which is the most common pediatric cancer. unfortunately, high dose mtx has several undesirable side effects and mtx toxicity vastly differs from patient to patient. * the pharmacokinetics of mtx were assessed with regards to the relevance of several different patient specific factors in 291 pediatric patients, who were administered with high dose of mtx. population pharmacokinetics of mtx analysis was performed by using nonlinear mixed effects modeling. * the final model was validated using nonparametric bootstrap analysis. body surface area (bsa), pre-hydration, baseline serum creatinine and 24 h creatinine clearance rate were statistically significant covariates for distributional volume (v) and renal clearance (cl). herein, is the first report of analysis of the importance of a series of patient factors on pharmacokinetics of mtx by one-compartment model. using these data, we have established an efficient population pharmacokinetic model for mtx, which can be used to predict safe clinical application of mtx especially in children with all.

Eligibility criteria:
inclusion criteria: * acute lymphoblastic leukemia and non-hodgkin's lymphoma younger than 18 years old exclusion criteria: * non lymphoblastic malignancies or older than 18 years

Keywords: methotrexate, pharmacokinetic acute lymphoblastic leukemia model
systematic withdrawal of neurohumoral blocker therapy in optimally responding crt patients

Conditions: Heart Failure (HF)

Summary: the primary objective of this study is to demonstrate that in patients with recuperated/normalized left ventricular function, defined as an ejection fraction (ef) ≥ 50%, after implantation of cardiac resynchronization therapy, device treatment is sufficient and neurohumoral blocker therapy can safely be withdrawn


Eligibility criteria:
inclusion criteria: * ≥18 years * crt implantation * based on class i recommendations of esc (european society of cardiology) guidelines: * left bundle branch block (lbbb) with qrs duration \>150 ms and left ventricular ejection fraction (lvef) ≤35% who remained nyha functional class ii, iii and ambulatory iv despite adequate medical treatment * lbbb with qrs duration 120-150 ms and lvef ≤ 35% who remain in nyha functional class ii, iii and ambulatory iv despite adequate medical treatment * at the moment of inclusion: ≥ 6 months after implantation * at the moment of inclusion: normalised lvef (≥ 50%), lvidd/bsa (left ventricular internal diastolic diameter indexed to body surface area) ≤3.2 cm/m²(woman) en ≤3.1 cm/m² (men) or lvdv/bsa (left ventricular diastolic volume indexed to body surface area) ≤75 ml/m² (women) or ≤75 ml/m² (men) * euvolemic clinical state and functioning in nyha class i exclusion criteria: * contraindication for withdrawal of ace-i/arb such as diabetic nephropathy and proteinuria \> 1g / 24 h * severe ventricular arrythmia (sustained vt or ventricular fibrillation) occuring at the time lv function was normalized * ischemic cardiomyopathy with evidence of scarring (scarring on mri or severe hypokinesia/akinesia in \>1 lv wall segment on echocardiography) * known severe coronary atherosclerosis (stenosis ≥ 80%)

Keywords: neurohumoral blocker therapy renin-angiotensin-aldosterone system (raas) raas-blocker beta blocker spironolactone angiotensin converting enzyme inhibitor (ace-i) angiotensin receptor blocker (arb) cardiac resynchronization therapy (crt) heart failure dyssynchrony left bundle branch block
collagen crosslinking with ultraviolet-a in asymmetric corneas

Conditions: Keratoconus; Ectasia; Degeneration

Summary: to evaluate the efficacy of ultraviolet-a (uva)-induced cross-linking of corneal collagen (cxl) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using uva light and the photo- mediator riboflavin. the purpose of this study is to generate data for presentation at medical meetings and for peer-review publication


Eligibility criteria:
inclusion criteria: * 8 years of age or older * diagnosis of keratoconus, post-lasik ectasia, or pellucid marginal degeneration or forme fruste pellucid marginal degeneration. * diagnosis of ffkc * history of radial keratotomy with fluctuating vision. * terrien's marginal degeneration * ability to provide written informed consent * likely to complete all study visits * minimum corneal thickness of at least 300 250 microns measured by ultrasound or pentacam for all indications other than terriens. for terriens, the minimal corneal thickness should be consistent with the surgeon's best surgical judgment. exclusion criteria: * severe corneal scarring that markedly affects vision * contraindications to any study medications or their components * pregnancy or breast feeding * active herpes corneal disease

Keywords: diagnosis of keratoconus, post-lasik ectasia, ffkc, or pellucid marginal degeneration